Federal Judge Won’t Adopt Blanket Immunity In Eliquis Death Case

Mealey's (May 4, 2016, 12:00 PM EDT) -- HONOLULU — A Hawaii federal judge on April 19 denied dismissal of a plaintiff’s design defect claim in an Eliquis wrongful death lawsuit, ruling that Hawaii courts have not interpreted the Restatement (Second) of Torts Section 402A to provide blanket immunity to all prescription drug manufacturers (Patricia Segovia, et al. v. Bristol-Myers Squibb Company, et al., No. 15-519, D. Hawaii; 2016 U.S. Dist. LEXIS 52405).

(Opinion available. Document #28-160505-016Z.)

In late 2013, Thomas Segovia’s doctor switched him from Coumadin-brand warfarin anticoagulant to Eliquis to prevent clots...
To view the full article, register now.